According to a press release on Global Newswire, Novartis has received a positive opinion on Cosentyx® from the Committee for Medicinal Products for Human Use (CHMP). This positive opinion…
According to a story from Healio, a recent study that was published in the scientific journal BMC Rheumatology revealed that it was uncommon for patients living with ankylosing spondylitis to switch from…
According to a story from Acrofan, the biotechnology company Clover Pharmaceuticals Inc. has recently announced that the first patient has been dosed in its phase 3 clinical study. This study…
According to a story from Ankylosing Spondylitis News, the results of a recent phase 2/3 clinical trial indicate that the drug upadacitinib (marketed as Rinvoq) can be an effective treatment…
According to a story from Healio findings from three studies indicate that the drugs bimekizumab and certolizumab pegol had the potential to be useful treatments for patients with axial spondyloathritis.…
According to a story from The Rheumatologist, a common treatment method for ankylosing spondylitis, a form of rare arthritis the affects the sacroiliac joints and spine, is a class of…
According to a story from Ankylosing Spondylitis News, findings from a phase 3 clinical trial suggest that the drug secukinumab (marketed as Cosentyx) could be an effective treatment for non-radiographic…
According to a story from Ankylosing Spondylitis News, a recent study has found that moxibustion, a form of heat therapy, could provide short-term benefits for patients with the rare disease…
According to a press release from Eli Lilly and Company, the US Food and Drug Administration (FDA) recently granted market approval to Lilly's ankylosing spondylitis drug, Taltz (ixekizumab). About Ankylosing…
According to a story from Markets Insider, Eli Lilly and Company recently announced that the US Food and Drug Administration (FDA) has approved the company's drug ixekizumab (marketed as Taltz®)…
According to a story from Ankylosing Spondylitis News, the drug Hadlima, which is a biosimilar to the drug Humira (adalimumab), was recently approved by the US Food and Drug Administration…
According to a publication from Ankylosing Spondylitis News, a recent study published in BMC Musculoskeletal Disorders suggests that LINC00311, a lengthy RNA molecule, is over-expressed in individuals with ankylosing spondylitis.…
According to a story from Ankylosing Spondylitis News, a recent study has found that the class of drugs known as tumor necrosis factor (TNF) inhibitors may actually be safer for…
A recent article written by Craig Klugman debates the ethical obligations pharmaceutical companies have to conduct clinical trials for drugs which have a likely potential to benefit a patient population…
A New AS Study A recent study, published in Reumatologia aimed to evaluate how ankylosing spondylitis (AS) patients are coping with their condition on a psychological level. They wanted to investigate…
When you or your child is first diagnosed with a rare disease it can be so difficult to know where to turn. You want to learn everything about the condition,…
According to a story from Ankylosing Spondylitis News, a recent study has reaffirmed the understanding that patients with ankylosing spondylitis, a rare form of inflammatory disease that affects the joints…
According to a story from Healio, a recent study has found that 58 percent of patients with the inflammatory disease ankylosing spondylitis will experience relapse within one year after stopping…
GO-ALIVE GO-ALIVE was a Phase 3 clinical trial examining the safety and the efficacy of Simponi Aria in ankylosing spondylitis (AS). Simponi was first approved by the FDA in 2009.…
The most common treatment for autoimmune conditions such as ankylosing spondylitis, plaque psoriasis, Crohn's disease, juvenile idiopathic arthritis, and rheumatoid arthritis is currently a drug called Humira, created by AbbVie.…
According to a story from mdmag.com, the publication recently conducted an interview with Dr. Eric Ruderman. Eric is a professor at Northwestern University with the Division of Rheumatology. The magazine…
According to a story from globenewswire.com, Galapagos NV and Gilead Sciences, Inc., recently announced that two clinical trials which were recently published in The Lancet demonstrated that the experimental treatment filgotinib could…
According to a recent press release, patients living with ankylosing spondylitis may soon have another treatment option. The researchers studying the new treatment, known as ixekizumab, recently posted results from…
According to a story from Medical Xpress, a team of scientists from Michigan State University have managed to reveal the manner in which a genetic malfunction can lead to the…
According to a story from the Vancouver Sun, the College of Physicians and Surgeons of B.C. recently issued new requirements in regards to the usage of opioids for treating patients…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
